Despite the correlation of GVT and GVHD, indirect evidence for a GVT reaction separate from GVHD has been reported in large cohorts of HCT patients or when DLI is administered to induce remission in HCT patients who have experienced a relapse.1,2 GVT activity can be increased by targeted therapy, as has been shown with sorafenib in FLT3 internal tandem duplication–mutant leukemia cells.3 The gene discussed is FLT3; the disease is graft versus host disease.